LG to complete phase II study for sustained human growth hormone.
Published: 2005-09-28 06:57:00
Updated: 2005-09-28 06:57:00
LG Life Science announced that a sustained type of human growth hormone, LB03002, had successfully completed its phase II study in Europe for the treatment of low height children, the study of which will be presented in the jointed ESPE/LWPES 2005 on Sept. 23.
LB03002 is a biotech new drug and...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
